Lupin hit 52-week high as investors cheer stellar Q2 earnings

Sales in the US market surged over 40 percent on year in Q2.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Lupin rose around 2 percent and hit a 52-week high of Rs 1,232.10 in the opening trade on November 9, a day after the pharma company reported a stellar set of earnings for the July-September quarter, impressing investors on all three fronts of revenue, net profit and profitability.

The drugmaker's net profit surged manifold to Rs 489.67 crore, sharply up from Rs 129.73 crore in the year-ago period. The jump in profit was aided by strong revenue, which grew over 20 percent on year to Rs 4,939.20 crore. The revenue growth was driven by strong US sales following the launch of the blockbuster respiratory drug Spiriva during the quarter.

"We delivered growth across all our target geographies, while managing costs and achieving operating leverage, thereby driving strong topline and bottomline growth," Nilesh Gupta, Managing Director, Lupin Limited, said in an exchange filing.

At 9.23 am, Lupin was trading a percent higher from the previous close at Rs 1,221.10 on the National Stock Exchange.

Follow our live blog for all the market action

The US sales for the drugmaker surged over 40 percent on-year to Rs 1,866.60 crore and made up 38 percent of Lupin’s global sales.

Revenue from Rest of the World Markets also surged twofold to Rs 199 crore. However, the India market underperformed, growing just 7 percent following weaker acute sales due to a sporadic monsoon, resulting in slower offtake in viral infections.

The company's operational performance also improved dramatically as the EBITDA margin expanded 800 basis points on year to 19.4 percent.

Analysts were anticipating Lupin to deliver the strongest set of results within the pharma space, largely due to expectations of strong US sales due to the launch of Spiriva.

The company had been struggling with lower margins for some quarters and the sharp improvement on the operational front also seemed to be cheered by investors.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.